458 related articles for article (PubMed ID: 19187194)
21. Management of haemophilic patients with inhibitors in major orthopaedic surgery by immunadsorption, substitution of factor VIII and recombinant factor VIIa (NovoSeven): a single centre experience.
Habermann B; Hochmuth K; Hovy L; Scharrer I; Kurth AH
Haemophilia; 2004 Nov; 10(6):705-12. PubMed ID: 15569165
[TBL] [Abstract][Full Text] [Related]
22. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience.
Nicolaisen EM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S119-23. PubMed ID: 9819042
[TBL] [Abstract][Full Text] [Related]
23. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O
Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322
[TBL] [Abstract][Full Text] [Related]
24. [Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in hemophilia].
Levi M; Friederich PW; van der Meer J
Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2534-7. PubMed ID: 12532665
[TBL] [Abstract][Full Text] [Related]
25. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
[TBL] [Abstract][Full Text] [Related]
26. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
Stewart AJ; Hanley JP; Ludlam CA
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S93-5. PubMed ID: 9819036
[TBL] [Abstract][Full Text] [Related]
27. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
[TBL] [Abstract][Full Text] [Related]
28. Recombinant activated factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment.
Lusher JM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S111-4. PubMed ID: 9819040
[TBL] [Abstract][Full Text] [Related]
29. Recombinant factor VIIa reduces bleeding risk in patients on platelet aggregation inhibitors immediately prior to renal transplantation--a retrospective analysis.
Loertzer H; Soukup J; Fornara P
Urol Int; 2007; 78(2):135-9. PubMed ID: 17293653
[TBL] [Abstract][Full Text] [Related]
30. [Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - Recommendations from the GTH experts].
Auerswald G; Muntean W; Kemkes-Matthes B; Klamroth R; Krause M; Kurnik K; Oldenburg J; Pabinger-Fasching I; Schramm W; Zimmermann R; Zotz RB
Hamostaseologie; 2009 May; 29(2):197-203. PubMed ID: 19404511
[TBL] [Abstract][Full Text] [Related]
31. Home treatment with recombinant activated factor VII: results from one centre.
Ingerslev J; Thykjaer H; Kudsk Jensen O; Fredberg U
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S107-10. PubMed ID: 9819039
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
Elwatidy S; Jamjoom Z; Elgamal E; Zakaria A; Turkistani A; El-Dawlatly A
Spine (Phila Pa 1976); 2008 Nov; 33(24):2577-80. PubMed ID: 19011538
[TBL] [Abstract][Full Text] [Related]
33. Recombinant factor VIIa.
Aitken MG
Emerg Med Australas; 2004; 16(5-6):446-55. PubMed ID: 15537408
[TBL] [Abstract][Full Text] [Related]
34. Continuous infusion of recombinant factor VIIa: continue or not?
Ewenstein BM
Thromb Haemost; 2001 Oct; 86(4):942-4. PubMed ID: 11686349
[No Abstract] [Full Text] [Related]
35. The role of recombinant activated factor VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors.
Castaman G
Blood Transfus; 2017 Sep; 15(5):478-486. PubMed ID: 28686157
[TBL] [Abstract][Full Text] [Related]
36. Single pretransplant bolus of recombinant activated factor VII ameliorates influence of risk factors for blood loss during orthotopic liver transplantation.
Kaliciński P; Markiewicz M; Kamiński A; Laniewski P; Ismail H; Drewniak T; Szymczak M; Nachulewicz P; Jezierska E
Pediatr Transplant; 2005 Jun; 9(3):299-304. PubMed ID: 15910384
[TBL] [Abstract][Full Text] [Related]
37. The intraoperative use of recombinant FVIIa in child with hemophilia A with antibodies.
Simic D; Milojevic I
Paediatr Anaesth; 2007 Aug; 17(8):789-92. PubMed ID: 17596224
[TBL] [Abstract][Full Text] [Related]
38. Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.
Bowman LJ; Uber WE; Stroud MR; Christiansen LR; Lazarchick J; Crumbley AJ; Kratz JM; Toole JM; Crawford FA; Ikonomidis JS
Ann Thorac Surg; 2008 May; 85(5):1669-76; discussion 1676-7. PubMed ID: 18442563
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.
Treur MJ; McCracken F; Heeg B; Joshi AV; Botteman MF; De Charro F; Van Hout B
Haemophilia; 2009 Mar; 15(2):420-36. PubMed ID: 19335751
[TBL] [Abstract][Full Text] [Related]
40. Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE).
Gruppo RA; Kessler CM; Neufeld EJ; Cooper DL
Haemophilia; 2013 Jul; 19(4):524-32. PubMed ID: 23551918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
